![](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/thumbnail/S266704962300025X:gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w96p5LBcBpyJTqfwgorxm+Ow=)
Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study
Introduction and objective Teriflunomide is an oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). We examined teriflunomide outcomes in patients with RRMS under clinical practice conditions in Spain. Material and methods […]